X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-05 | ZYME | Smith Jeffrey T L | EVP, Chief Medical Officer | S - Sale+OE | $25.10 | -10,538 | 18,352 | -36% | -$264,471 | |||||
| D | 2026-01-05 | ZYME | Galbraith Kenneth | Chair, CEO | S - Sale+OE | $25.10 | -54,343 | 193,266 | -22% | -$1,363,841 | |||||
| D | 2026-01-05 | ZYME | Moore Paul Andrew | Chief Scientific Officer | S - Sale+OE | $25.10 | -20,110 | 40,391 | -33% | -$504,699 | |||||
| D | 2025-12-22 | ZYME | Galbraith Kenneth | Chair, CEO | S - Sale+OE | $27.02 | -47,528 | 133,275 | -26% | -$1,284,311 | |||||
| M | 2025-05-15 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $11.47 | +55,421 | 17,883,908 | 0% | +$635,586 | |||||
| M | 2025-04-16 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $11.32 | +128,713 | 17,828,487 | +1% | +$1,456,408 | |||||
| M | 2025-04-03 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $11.42 | +317,208 | 17,699,774 | +2% | +$3,623,970 | |||||
| M | 2025-03-31 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $11.75 | +127,415 | 17,382,566 | +1% | +$1,497,322 | |||||
| M | 2025-03-25 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $12.61 | +97,349 | 17,255,151 | +1% | +$1,227,309 | |||||
| M | 2025-03-20 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $12.92 | +127,198 | 17,157,802 | +1% | +$1,643,248 | |||||
| M | 2025-03-17 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $12.55 | +228,463 | 17,030,604 | +1% | +$2,866,553 | |||||
| M | 2025-03-11 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $12.13 | +1,081,980 | 16,802,141 | +7% | +$13,120,914 | |||||
| M | 2025-01-16 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $13.88 | +141,429 | 15,720,161 | +1% | +$1,963,538 | |||||
| M | 2025-01-13 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $13.59 | +167,654 | 15,578,732 | +1% | +$2,278,811 | |||||
| M | 2025-01-08 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $13.21 | +225,119 | 15,411,078 | +1% | +$2,974,819 | |||||
| D | 2025-01-06 | ZYME | Moore Paul Andrew | Chief Scientific Officer | S - Sale+OE | $14.92 | -21,200 | 23,333 | -48% | -$316,391 | |||||
| D | 2025-01-06 | ZYME | Galbraith Kenneth | Chair, CEO | S - Sale+OE | $14.92 | -57,291 | 80,803 | -41% | -$855,017 | |||||
| D | 2025-01-06 | ZYME | Smith Jeffrey T L | EVP, Chief Medical Officer | S - Sale+OE | $14.92 | -11,110 | 8,890 | -56% | -$165,807 | |||||
| M | 2024-12-30 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $14.64 | +363,369 | 15,185,959 | +2% | +$5,321,176 | |||||
| M | 2024-12-24 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $14.44 | +130,309 | 14,822,590 | +1% | +$1,882,115 | |||||
| AM | 2024-12-19 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $13.98 | +1,254,808 | 14,692,281 | +9% | +$17,544,284 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |